The effect of Des-Arg9-bradykinin and bradykinin-potentiating peptide C on isolated rat hearts.
OBJECTIVE
Des-Arg9-bradykinin and bradykinin-potentiating peptide C (BPPC) may contribute to the regulation of cardiovascular function. Therefore, we studied effects of these peptides on coronary perfusion pressure (CPP), heart rate, left ventricular developed pressure (LVDP) and maximum rate of increase of left ventricular pressure (+dP/dtmax).


METHODS
The isolated rat hearts were perfused with modified Krebs-Henseleit solution.


RESULTS
Infusion of 10, 100 and 1000 nM Des-Arg9-bradykinin decreased CPP (-13.6, -14.8 and -19.0%), LVDP (-16.5, -21.0 and -30.7%) and +dP/dtmax (-11.8, -17.8 and -23.7%), respectively (p < 0.001). Ten or 100 nM Des-Arg9-bradykinin did not alter heart rate, but 1000 nM increased it (+11.3%, p < 0.01). One, 10 and 100 nM BBPC reduced CPP (-16.3, -28.5 and -47.5%), LVDP (-12.6, -19.6 and -21.3%) and +dP/dtmax (-8.7, -18.6 and -20.3%), respectively (p < 0.001). BPPC increased heart rate at 1 nM (+9.6%, p < 0.05 ) and at 10 nM (+14.2%, p < 0.01), however 100 nM decreased it (-15.3%, p < 0.001).


CONCLUSIONS
This study evidences that Des-Arg9-bradykinin and BPPC possess vasodilatory effect with modest negative inotropic action. Furthermore, high-dose of Des-Arg9-bradykinin and low-dose of BPPC may produce a tachycardic action, but high dose of BBPC may cause a bradycardic action.
Eskisehir Osmangazi University, Medical Faculty Department of Physiology Meselik Kampusu 26480 Eskisehir Turkey.
Z
Z
Kaygısız
B
B
Kaygısız
E
E
Kılınç
D000818:Animals; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006321:Heart / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects*; D066298:In Vitro Techniques; D008297:Male; D020098:Natriuretic Peptide, C-Type / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley
D020098:Natriuretic Peptide, C-Type; C024626:bradykinin, des-Arg(9)-; D001920:Bradykinin